Sara Maichle, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 6000 S Holly St, Greenwood Village, CO 80111 Phone: 720-488-3405 |
Mr. Bob Edward Mandernack, P.PH. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 6061 S Willow Dr, Greenwood Village, CO 80111 Phone: 877-839-8121 Fax: 877-289-0617 |
Yevgeniya Lvovskiy Scherbak, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 4910 S Yosemite St, Greenwood Village, CO 80111 Phone: 303-773-2390 |
Nathan Dahlberg, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 6767 S Clinton St, Greenwood Village, CO 80112 Phone: 303-790-2583 |
Fatemeh Bighash Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 4910 S Yosemite St, Greenwood Village, CO 80111 Phone: 303-773-2390 Fax: 303-741-2563 |
Pete Zaharas Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 8200 E Belleview Ave Ste 416c, Greenwood Village, CO 80111 Phone: 303-771-3254 |
News Archive
Scientists from The University of Manchester working with IBM Research have identified a key biological mechanism that for the first time explains why women with dense breast tissue are at greater risk of developing breast cancer.
A University of Alberta researcher and Canada Excellence Research Chair in Virology has made the discovery of a vaccine that will potentially help combat hepatitis C. Michael Houghton, who led the team that discovered the hepatitis C virus in 1989, announced his findings at the Canada Excellence Research Chairs Summit in Vancouver this afternoon. Currently, there are no vaccines against the disease available.
Congressman John Culberson, R-Texas, today announced that his office will post the current healthcare bill in the House of Representatives, "H.R.3200 - America's Affordable Health Choices Act of 2009," on the congressman's Web site and, using a new technology, invite his constituents to participate in, comment on and debate the pending bill.
Researchers from across the world who are tacking the deadly bacterial disease tuberculosis (TB) attended a symposium at St George's, University of London to discuss the way forward in treatment and prevention.
Merus Labs International Inc. is pleased to announce that their wholly owned subsidiary, Merus Labs Inc. announces the execution of a definitive agreement with Innocoll Pharmaceuticals Limited to license in, on an exclusive basis, 3 advanced wound care products for the Canadian market. Furthermore, Innocoll agrees to grant to Merus a right of first refusal for all current pipeline advanced wound care products for the Canadian Market.
› Verified 5 days ago